Search company, investor...


Founded Year



Acquired | Acquired

Total Raised


About Spiration

Spiration was founded to develop treatments for chronic obstructive pulmonary disease.

Headquarters Location

6675 185th Avenue NE

Redmond, Washington, 98052,

United States


Missing: Spiration's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Spiration's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Spiration

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Spiration is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,383 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

Spiration Patents

Spiration has filed 133 patents.

The 3 most popular patent topics include:

  • Medical equipment
  • Surgical procedures and techniques
  • Surgery
patents chart

Application Date

Grant Date


Related Topics




Actuators, Molecular biology, Valves, Human positions, Ring forming reactions


Application Date


Grant Date



Related Topics

Actuators, Molecular biology, Valves, Human positions, Ring forming reactions



Latest Spiration News

Spiration valve system improves lung function in patients with emphysema over 5 years

Jun 5, 2023

Source: Disclosures: Criner reports receiving grants from AstraZeneca, Boehringer Ingelheim, Broncus, Chiesi, Corvus, Genentech, Gilead, GlaxoSmithKline, Fisher-Paykel Healthcare, Lilly, NIH-NHLBI, Novartis, Olympus, PA-DOH, Pfizer, Pearl, PneumRx, Pulmonx, Regeneron, Roche and Spiration; consultant fees from Almirall, AstraZeneca, Broncus, BTG, CSA Medical, GlaxoSmithKline, EOLO, Intuitive, Ion, Mereo, Nuvaira, PneumRx, Pulmonx, Regeneron and Sanofi; and equity interest from Free Flow Medical and Pleural Dynamics. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio A lung volume reduction treatment improved FEV1 in patients with emphysema. The number of serious adverse events in those who received the treatment was comparable to controls. WASHINGTON — Patients with severe emphysema had improved lung function at 5 years after receiving treatment with a support expiration valve system, according to research presented at the American Thoracic Society International Conference. Gerard J. Criner “Bronchoscopic lung volume reduction procedures are a durable treatment response compared to optimal medical therapy,” Gerard J. Criner, MD, FACP, FACCP, director of the Temple Lung Center and chair and professor of thoracic medicine and surgery at the Lewis Katz School of Medicine at Temple University, told Healio. Patients with severe emphysema had improved lung function at 5 years after receiving treatment with a support expiration valve system, according to research presented at the American Thoracic Society International Conference. Image: Adobe Stock Criner and colleagues evaluated 172 patients with severe emphysema in the EMPROVE trial to see if the Spiration Valve System (Olympus) was safe and effective over 5 years. As Healio previously reported , the Spiration Valve System showed sustained clinically significant benefit in health-related quality of life at 2 years in patients with severe emphysema. To assess differences in lung function from baseline over the span of 5 years, researchers utilized the mixed-effects model. Additionally, researchers calculated the rate of serious adverse events by finding out how many events took place 6 months after the procedure and dividing that by the remaining cumulative follow-up patient-years. Of the total cohort, 113 patients received Spiration Valve System treatment and 59 patients were a part of the control group. Following the procedure, patients demonstrated a 0.1098 L increase (P < .001) in lung function, or FEV1; however, this measure was found to fall by 0.044 L per year (P < .001) in both these patients and control patients, according to the abstract. With the two groups showing a comparable rate of decline, researchers assumed that disease progression was occurring at a “steady rate,” signaling that patients who underwent the valve placement procedure instantly got approximately 2.5 years of improvement in FEV1. When evaluating all serious adverse events, the rate was comparable between both sets of patients, with a rate of 0.6, or 210 events in 5 years, in the treatment group, and 0.48, or 35 events in 2 years, in the control group since researchers only followed control patients for 2 years. Notably, the rate of pneumothorax in the treatment group was 0.21, or 75 events in 5 years, and 0 in the control group, according to the abstract. In terms of increasing lung function, researchers deemed the treatment “safe and durable” based on the above findings. “This affirms the prior data with use of lung volume reduction surgery and non-controlled cohort follow-ups post bronchoscopic lung volume reduction that patients have a durable treatment response,” Criner told Healio. Read more about

Spiration Frequently Asked Questions (FAQ)

  • When was Spiration founded?

    Spiration was founded in 1999.

  • Where is Spiration's headquarters?

    Spiration's headquarters is located at 6675 185th Avenue NE, Redmond.

  • What is Spiration's latest funding round?

    Spiration's latest funding round is Acquired.

  • How much did Spiration raise?

    Spiration raised a total of $108.45M.

  • Who are the investors of Spiration?

    Investors of Spiration include Olympus, Olympus Corporation of the Americas, Three Arch Partners, New Enterprise Associates, Versant Ventures and 8 more.

  • Who are Spiration's competitors?

    Competitors of Spiration include CVRx, TxCell, Conatus Pharmaceuticals, Advanced Biohealing, Arginetix and 9 more.

Compare Spiration to Competitors


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.


Antipodean is a pharmaceutical company developing treatments for neurodegenerative diseases such as Parkinson's Disease and Friedreich's Ataxia that are associated with mitochondrial dysfunction.


Asterion is a manufacturer of analog semiconductors.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

ISW Group

ISW Group is a pharmaceutical company that researches and aims to develop FDA approved topical products for the management and treatment of acute and chronic inflammatory skin conditions. ISW Group's research program focuses on acute and chronic dermatologic irritation and inflammation associated with dermatitis, Pseudofolliculitis barbae, burn care and wound healing.

Alacrity Biosciences

Alacrity Biosciences is a biopharmaceutical company focused on acquiring, developing and commercializing therapeutics to treat ophthalmic diseases that threaten vision and reduce patient quality of life.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.